Should I Buy BFRI? BFRI 2026 Analysis

Should You Buy Biofrontera Inc (BFRI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.820

1 Day change

-2.03%

52 Week Range

1.190

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: no Intellectia buy signals, weak near-term statistical trend, and deteriorating top-line growth.
Pre-market price (0.859) is sitting just above key support (S1 0.851); downside risk is immediate if support breaks.
With no news catalysts and neutral institutional/insider activity, there’s no clear trigger for a fast upside move (important for an impatient entry).

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.00426) and expanding lower → bearish momentum still building.
RSI(6)=28.281 → near-oversold conditions, but oversold alone isn’t a buy trigger without momentum stabilization.
Moving averages: SMA_5 > SMA_20 > SMA_200 suggests a constructive broader setup, but current momentum contradicts it (likely a pullback within a larger base).
Key levels: Pivot 0.928 (price below pivot = bearish bias). Support: 0.851 then 0.804. Resistance: 1.004 then 1.051.
Pattern-based forward bias (similar candlesticks): modeled odds point to further weakness (-1.08% next day, -2.3% next week, -6.16% next month).

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

and near-oversold on RSI, which can enable short technical bounces if selling pressure fades.
can help if momentum flips back up.

Neutral/Negative Catalysts

- No news in the last week → no clear event-driven catalyst to reverse the current downswing.
- Bearish momentum is strengthening (MACD negative and expanding).
- Price is below pivot (0.928); overhead supply likely until reclaimed.
- Model-based trend projection is consistently negative over 1D/1W/1M horizons.
- Trading trends: Hedge funds neutral; insiders neutral → no supportive “smart money” signal recently.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 6,988,000, down -22.46% YoY → clear top-line contraction.
Net income: -6,649,000 (still a loss) but improved 17.29% YoY → cost/expense control helped.
EPS: -0.62, down -36.73% YoY → per-share performance worsened despite net income improvement.
Gross margin: 70.74%, up +54.18% YoY → margin strength is the main bright spot, but it hasn’t translated into earnings leverage yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating changes or price target updates were provided in the data, so there’s no clear read on recent Wall Street sentiment shifts.
Current “pros vs cons” from available data: Pros = sharply higher gross margin and constructive longer-term moving-average structure; Cons = contracting revenue, worsening EPS, and bearish near-term momentum/forecast.

2 Analyst Rating

Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6 USD with a low forecast of 3 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.838

Low

Averages

High

Current: 0.838

Low

Averages

High

Roth Capital

Buy

upgrade

$8 -> $10

AI Analysis

2025-06-30

Reason

Roth Capital

Price Target

$8 -> $10

AI Analysis

2025-06-30

upgrade

Buy

Reason

Roth Capital raised the firm's price target on Biofrontera Inc. to $10 from $8 and keeps a Buy rating on the shares. The firm notes Biofrontera Inc. acquired full U.S. Ameluz and RhodoLED rights from former parent company Biofrontera AG, which, when combined with the $11M investment from existing institutional investors, funds Biofrontera Inc. to profitability.

Benchmark

Bruce Jackson

Buy

downgrade

2025-05-19

Reason

Benchmark

Bruce Jackson

Price Target

2025-05-19

downgrade

Buy

Reason

Benchmark analyst Bruce Jackson lowered the firm's price target on Biofrontera Inc. to $2.75 from $7 and keeps a Buy rating on the shares. After Q1 revenue of $8.6M lagged the firm's $10.6M estimate, its new revenue estimate is $41.1M for 2025, down from $43.1M, notes the analyst, who adds that historic sales patterns would suggest that the "already seasonally heavy" Q4 will be "the key to this year's revenue growth."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BFRI

Unlock Now

BFRI Should I Buy

BFRI Should I Buy

Should You Buy Biofrontera Inc (BFRI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch